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Abstract
Background: Ovarian cancer remains a leading cause of death in women and development of new therapies is essential.
Second mitochondria derived activator of caspase (SMAC) has been described to sensitize for apoptosis. We have explored
the pro-apoptotic activity of LBW242, a mimic of SMAC/DIABLO, on ovarian cancer cell lines (A2780 cells and its
chemoresistant derivative A2780/ADR, SKOV3 and HEY cells) and in primary ovarian cancer cells. The effects of LBW242 on
ovarian cancer cell lines and primary ovarian cancer cells was determined by cell proliferation, apoptosis and biochemical
assays.
Principal Findings: LBW242 added alone elicited only a moderate pro-apoptotic effect; however, it strongly synergizes with
tumor necrosis factor-related apoptosis inducing ligand (TRAIL) or anticancer drugs in inducing apoptosis of both ovarian
cancer cell lines and primary ovarian cancer cells. Mechanistic studies show that LBW242-induced apoptosis in ovarian
cancer cells is associated with activation of caspase-8. In line with this mechanism, c-FLIP overexpression inhibits LBW242-
mediated apoptosis.
Conclusion: LBW242 sensitizes ovarian cancer cells to the antitumor effects of TRAIL and anticancer drugs commonly used
in clinic. These observations suggest that the SMAC/DIABLO mimic LBW242 could be of value for the development of
experimental strategies for treatment of ovarian cancer.
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Introduction
Cancer is very complex multistep disorder involving the
progressive accumulation of genetic and epigenetic abnormalities,
which ultimately lead to the transformation of normal cells into
malignant cells displaying the essential properties of cancer:
resistance to apoptotic mechanisms, independency from growth
signals, insensitivity to negative growth signals, invasive and
metastatic capacities, unlimited replicative potential and sustained
angiogenesis [1]. Among these various properties of cancer cells,
the resistance to apoptosis certainly plays a very relevant role in
tumor development and progression. The ability of cancer cells to
evade apoptosis is related to various biochemical properties of
these cells, and particularly, to the up-regulation of antiapoptotic
genes such as certain members of the Bcl-2 family of proteins and
members of the Inhibitor of Apoptosis (IAP) family of proteins [2].
Particularly, three lines of evidence support a role for IAP proteins
in cancer: (i) elevated expression levels of IAP proteins, particularly
XIAP, c-IAP1 and c-IAP2, in a number of human cancer types
correlate with tumor grade and prognosis [3]; (ii) a number of in
vitro and in vivo studies have shown that downregulation of XIAP or
c-IAP1 by various agents results in sensitization of cancer cells to
chemotherapy- and gamma irradiation-induced apoptosis [4]; (iii)
the chromosomal region 11q21-q23 containing c-IAP1 and c-
IAP2 genes is subject to chromosomal amplification in various
tumors [3,4].
IAPs, and particularly c-IAP1, c-IAP2 and X-linked IAP
(XIAP), function to inhibit apoptosis by preventing activation of
caspases-8 or inhibiting the activity of caspases-9, -3 and -7,
respectively [5,6]. C-IAP1 and c-IAP2 possess an E3 ubiquitin
ligase domain that promotes proteasome-dependent degradation
of c-IAP1 and c-IAP2 [7]. The activity of IAPs is antagonized by
SMAC/DIABLO (second-mitochondria-derived activator of cas-
pases/direct inhibitor of apoptosis-binding protein with low pI)
that, after release from mitochondria in response to apoptotic
triggering, undergoes maturation and cleavage of its N-terminal
region, with consequent exposure of the AVPI sequence [8]. This
tetrapepetide binds XIAP and competes with the same binding
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Through this mechanism, SMAC/DIABLO prevents the seques-
tration of caspases by IAPs, thus facilitating the apoptotic pathway.
Since the AVPI sequence is able to promote apoptosis, compounds
able to mimic this tetrapeptide, collectively known as SMAC-
mimetics, have represented the objective of intensive research
efforts and several of these agents have been developed during
these last years [10–15].
It is important to note that a deregulation of IAPs may
contribute to tumor development not only through caspases
inactivation, but also through different mechanisms not dependent
on caspases inactivation. Thus, a recent study clearly showed that:
XIAP contributes to metastasis in vivo and cell invasion in vitro,
independently of caspases binding and inhibition; XIAP in
complex with survivin drives the activation of NF-kB to promote
cell invasion and metastasis; c-IAP1 and c-IAP2 are also involved
in cancer cell invasion [16].
Thus, inactivation of IAPs, particularly when combined with
other treatments (such as chemotherapic drugs, death ligands
including TNF-alpha and TRAIL), results in the death of most
tumor cells, at least under tissue culture conditions [11,13,16,17].
Importantly, inactivation of IAPs does not seem to be detrimental
to normal cells. The ensemble of these observations has supported
the development of small pharmacological inhibitors of IAPs that
have been introduced in phase I clinical trials [5].
LBW242 is a peptidomimetic targeting IAPs recently reported
by Zawel and coworkers which competes with high affinity with
SMAC/DIABLO for occupancy of the XIAP BIR3 binding
pocket [17]. This compound was shown to be able to induce
apoptosis of various cell types including multiple myeloma, acute
myeloid leukemia, glioblastoma and melanoma [18–21].
In the present study we have explored the capacity of LBW242
to induce apoptotic cell death of ovarian cancer cells added alone
or in combination with either TRAIL or anticancer drugs. Our
results indicate that LBW242 improves the sensitivity of ovarian
cancer cell death induced by either TRAIL or anticancer drugs
such as Topotecan through an effect related to a potentiation of
caspase-8 activation. These observations support future studies to
investigate a possible role of LBW242 in ovarian cancer treatment.
Methods
Ethics statement
This study was specifically approved by the Institutional Review
Board of the Istituto Superiore di Sanita ` and was in accordance
with the principles of the Helsinki Declaration II. The written
informed content was obtained from each patient.
Cell Culture
Cisplatin-sensitive human ovarian epithelial carcinoma cell line
A2780WT was obtained from the American Type Culture
Collection (ATCC); adriamycin-resistant cell line A2780ADR,
derived from its parental ovarian cancer cell line A2780 by
applying stepwise increases in concentrations of adriamycin was
obtained from the European Collection of Cell Cultures
(ECACC). The A2780ADR cells were treated with 10 mM
adriamycin every 10 passages. SKOV3 and HEY cell lines were
obtained from ATCC.
The cells were cultured at 37uC in an atmosphere of 5% CO2 in
Advanced MEM with 3% fetal bovine serum (FBS, Euroclone,
Milan, Italy), 50 IU/ml penicillin, 50 mg/ml streptomycin, 50 mg/
ml gentamicin and 0,3 mg/ml glutamine. The cells were routinely
checked for the presence of mycoplasma.
Isolation and in vitro culture of primary ovarian cancer
cells
Intra-operatory biopsies have been obtained from 9 ovarian
cancer patients, affected by serous adenocarcinoma, undergoing
debulking surgery for either primary or relapsing disease. Tumor
tissue has been mechanically dissociated with a scissor and a tumor
cell suspension has been obtained by digestion in tissue culture
medium (RPMI 1640) containing collagenase, deoxyribonuclease I
and hyaluronidase. The final tumor cell suspension was checked
for the proportion of tumor cells by standard cytology and the
percentage of epithelial cells by flow cytometry (determined after
staining with Ber-EP4 mAb, Dakopatt, Copenaghen, Denmark).
Briefly, for the evaluation of Ber-EP4 reactivity cell aliquots were
stained 30 min at 4uC with 5 mg/ml FITC-labeled anti-Ber-EP4
mAb, washed and analysed for fluorescence emission using
a Becton Dickinson flow cytometer. Tumor cell aliquots (1610
6
cells) have been plated into 25 cm
3 tissue culture flasks in 10 ml of
cell culture medium containing 10% fetal calf serum. After 1 day
of in vitro culture, non-adherent cells (containing tissue debris and
dead cells) have been removed and fresh medium was added to the
culture and then incubated for additional 24 hours either in the
absence or in the presence of TRAIL, or LBW242 or both
reagents. At 24 hours of culture cells were confluent. Tumor
cultures contained at least 80% of tumor cells.
Transduction of A2780WT, A2780ADR and SKOV3 cells
A2780WT, A2780ADR and SKOV3 cells expressing either the
empty vector PINCO-GFP (PINCO) or the vector PINCO-GFP
containing the c-FLIPL (FLIP) human gene have been obtained as
previously reported [22]. Transduced cells were routinely analyzed
for GFP expression using a flow cytometer and for c-FLIPL
expression by Western blotting.
Apoptosis assessment by Annexin–V staining
After drug treatments, cells were resuspended in 200 ml staining
solution (containing Annexin-V fluorescein and Propidium Iodide
in a Hepes buffer, Annexin-V-FITC Apoptosis Detection Kit,
Pharmingen, San Jose, Ca, USA). Following incubation at room
temperature for 15 min., cells were analyzed by flow cytometry.
Annexin-V binds to those cells that express phosphatidylserine on
the outer layer of the cell membrane, and propidium iodide stains
the cellular DNA of those cells with a compromised cell
membrane. This allows for the discrimination of live cells
(unstained with either fluorochrome) from apoptotic cells (stained
only with annexin V) and necrotic cells (stained with both
Annexin-V and Propidium Iodide).
Quantification of apoptosis and cell cycle analysis by
propidium iodide/fluorescence activated cell sorting
Cells were harvested with trypsin, washed, incubated first with
a spermine tetrahydrochloride detergent buffer containing trypsin
to digest cell membranes and cytoskeletons, then with a citrate
buffer containing a trypsin inhibitor and ribonuclease A to inhibit
trypsin activity and to digest the RNA and, finally, resuspended in
400 ml of propidium iodide (PI) solution (50 mg/ml PI, 0,1%
Triton X-100, and 0,1% sodium citrate in PBS) (Cycle Plus DNA
Staining Kit, Becton Dickinson, USA). The cells were then
analyzed by flow cytometry using a software dedicated for DNA
analysis (ModFit LT software, Verity Software House, Topsham,
ME, USA). The cells with subdiploid DNA content were
quantified to determine the percentage of cells containing
apoptotic, fragmented DNA.
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Ovarian cancer cells were preincubated with a pan-caspase
inhibitor, N-benzyloxy-carbonyl-Val-Ala-Asp(OMe)-fluoro-
methylketone (zVADfmk) or N-benzyloxy-carbonyl-Ile-
Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone (zIETDfmk), (both
from Sigma, St Louis, USA) before the addition of the various
compounds stimulating apoptosis.
The agonistic monoclonal antibodies to TRAIL-R1 (MAPA-
TUMUMAB) and TRAIL-R2 (LEXATUMUMAB) are fully
Figure 1. Effect of LBW242 on the cell growth (A) and apoptosis (B) of A2780WT, A2780ADR, HEY and SKOV3 cells. 1A- A2780WT,
A2780ADR, HEY and SKOV3 cells have been grown for 48h either in the absence or in the presence of TRAIL (50 ng/ml) and either in the absence or in
the presence of growing concentrations of LBW242 (from 1 to 10 mM) and at the end of the culture the number of living cells was determined. The
difference between Control and TRAIL was statistically significant: p=,0.001 for A2780WT and HEY; p=,0.01 for SKOV3; p=,0.05 for A2780ADR.
1B- A2780WT and SKOV3 cells have been grown as above and after 48 h of culture the proportion of apoptotic cells was determined by Annexin-V
binding assay and propide iodide staining. The percentage of apoptotic cells was determined by flow cytometry. The results represent the mean
values observed in three separate experiments. The difference between Control and TRAIL was statistically significant: p=,0.01 for both A2780WT
and SKOV3 cells.
doi:10.1371/journal.pone.0035073.g001
SMAC Mimic and Ovarian Cancer
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35073Figure 2. c-FLIPL overexpression protects A2780WT, A2780ADR and SKOV3 cells from the pro-apoptotic effects induced by
LBW242. A2780WT, A2780ADR and SKOV3 cells have been stably transfected with either an empty vector (PINCO) or with the vector containing the
cDNA of c-FLIP (FLIP) and the resulting cells were grown either in the absence ( Control ) or in the presence of LBW242 (10 mM) or TRAIL (50 ng/ml) or
both these agents at the above concentrations. The percentage of apoptotic cells was determined by flow cytometry using the Annexin-V/PI binding
assay. The data represent the mean values 6 SEM observed in three separate experiments. Statistical analysis: * p=,0.05; ** p=,0.01; ***
p=,0.001.
doi:10.1371/journal.pone.0035073.g002
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35073Figure 3. Effect of a pan-caspase inhibitor (zVAD-fmk) and a specific caspase-8 inhibitor (zIETD-fmk) on the induction of apoptosis
by LBW242 (LBW) or TRAIL or both agents. A2780WT, A2780FLIP, A2780ADR, A2780ADR FLIP, SKOV3 and SKOV3 FLIP cells have been grown as
reported in Fig. 2 either in the absence or in the presence of 40 mM zVAD-fmk or zIETD-fmk and after 48 h of incubation the percentage of apoptotic
cells was determined by Annexin-V/PI binding assay. The results represent mean values 6 SEM observed in three separate experiments.
doi:10.1371/journal.pone.0035073.g003
SMAC Mimic and Ovarian Cancer
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35073Figure 4. Immunoblotting analysis of XIAP, c-IAP1, c-IAP2, Survivin, Casp-9, Casp-8, c-FLIPL, FADD, PARP, Casp-3 and BID in
A2780WT PINCO and FLIP (A), A2780ADR PINCO and FLIP (B), SKOV3 PINCO and SKOV3 FLIP (C) cells grown for 24 h either in the
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provided by Human Genome Science (Rockville, MD, USA).
Treatment with anticancer drugs
In some experiments ovarian cancer cells have been incubated
with some anticancer drugs commonly used in ovarian cancer
therapy: cis-diamineplatinum(II)chloride (CPLAT); paclitaxel
(TAXOL); Topotecan Hydrichloride Hydrate (TOPO); Etoposide
(ETOPO); Doxorubicin Hydrochloride (DOXO). All these drugs
were purchased from the Sigma Co (St Louis, USA) and were
added in vitro at two doses: a low dose corresponding to the mean
plasma peak level observed during drug infusions to cancer
patients (i.e., 1.67 mM for CPLAT; 2.45 mM for TAXOL;
0.21 mM; 8.5 mM for ETOPO; 0.17 mM for DOXO) and a high
dose, corresponding to a five fold higher dose than the low dose.
Western blot Analysis
Whole cell extracts were obtained lysing the cells in a buffer
containing 20 mM HEPES, 50 mM NaCl, 10 mM EDTA, 2 mM
EGTA, 0.5% NP-40, 1 mM DTT, 0,1 mM PMSF, 2 mg/ml
Leupeptin, 2 mg/ml Aprotinin, 25 mM NaF, and 10 mM
Na3VO4. After incubation for 30 min on ice, the protein lysates
were cleared of debris by centrifugation at 10,000 g for 10 min.
The protein concentration in the soluble supernatant, was
determined using the Bio-Rad protein assay (Bio-Rad, Richmond,
VA, USA).
Antibodies
Anti-caspase -9, -3 were purchased from Upstate (Upstate
Biotechnology Lake Placid NY, USA and R&D Systems Inc.
Minneapolis, MN, USA); Anti-XIAP and anti-Bcl-2 were
purchased from BD Pharmigen ( BD Pharmigen, San Diego,
USA); anti-survivin and anti-PARP were purchased from R&D
System (R&D System Inc., Minneapolis, MN); anti-FADD was
purchased from BioSource (BioSource, Camarillo, CA, USA);
anti-c-FLIP (clone NF6) and anti-c-IAP were purchased from
Alexis (Alexis Biochemicals, San Diego, CA, USA); anti-actin from
Oncogene (Oncogene research Products, Cambridge, MA), was
used as loading control.
Statistical Analysis
Statistical analysis was performed using the Graph Pad
Program. All parameters were reported as means 6 SEM. To
compare between group differences, robust ANOVA was
performed. The P-values reported were two-sided. A P-value of
less than 0.05 indicated statistical significance. Isobologram
analysis was performed using the CalcuSyn software program
(Biosoft, MO, and Cambridge, UK). A combination index (CI) less
than 1.0 indicates synergism, an a CI of 1.0 indicates additive
activity [25].
Results
LBW242 improves TRAIL-mediated cell death of ovarian
cancer cell lines
In our previous studies we showed the pro-apoptotic effect of
SMAC/DIABLO mimetic compound 3 in ovarian cancer cell
lines A2780WT and their resistant counterpart A2780DDP and
A2780ADR [26]. In the present study, we investigated the effect of
another SMAC/DIABLO mimetic, LBW242, on ovarian cancer
models. First, we explored the cell proliferation in a dose-response
test of LBW242 alone and in combination with TRAIL (FIG. 1A).
The cell line A2780WT (upper left panel) was only slightly inhibited
in its growth by LBW242 added alone; however, the combined
treatment of LBW242 with TRAIL resulted in a marked
synergistic inhibition of cell growth. The same kind of sensitivity
was observed for HEY cell line (lower left panel). Isobologram
analysis confirmed synergistic anti-tumor activity of LBW242 plus
TRAIL (for A2780WT CI=0.77 and HEY CI=0.80). The
synergistic interaction of LBW242 and TRAIL in A2780WT and
HEY cell lines can be intuitively visualized by plotting cell growth
data using measurements at LBW242 0 mM with and without
TRAIL as 100% and all the subsequent measurements expressed
relative to its own control (see Fig. S1). This figure reveals an
additional reduction in cell number caused by the addition of
LBW242 on the top of that induced by TRAIL alone (Fig. S1).
The A2780ADR and SKOV3 (right panels) cell lines were the
most sensible to the inhibitory effect of LBW242 on cell
proliferation, which was moderately increased by TRAIL
addition. Isobologram analysis showed an additive effect of
LBW242 plus TRAIL in inhibiting the growth of these cell lines
(for A2780ADR CI=0.97; for SKOV3 CI=1.0).
The same treatments were performed on A2780WT and
SKOV3 cell lines to evaluate the effect of LBW242 on the
percentage of apoptotic cells (Fig. 1B). The A2780WT cells were
scarcely sensitive to the single treatments with either LBW242 or
TRAIL alone, but very sensitive to the combined treatment
(CI=0.70). SKOV3 cells were sensitive to the pro-apoptotic effect
of LBW242, but scarcely sensitive to TRAIL; the combined
addition of the two drugs further increased the rate of apoptosis
(CI=0.79) (Fig. 1B).
These data indicate that: ovarian cancer cell lines are sensitive
to LBW242 effects, particularly in combined treatment with
TRAIL; LBW242 exerts a synergistic or additive anti-tumor
activity with TRAIL in ovarian cancer cell lines.
Experiments carried out using agonistic anti-TRAIL-R1
(MAPATUMUMAB) or anti-TRAIL-R2 (LEXATUMUMAB)
mAbs provided evidence that the latter one added together with
LBW242 induced a high rate of apoptosis of all the four ovarian
cancer cell lines here studied (data not shown).
c-FLIPL overexpression inhibits the pro-apoptotic effect
of LBW242
In previous studies it was demonstrated that under TNFa
stimulation, caspase-8 is a critical apoptotic protease in IAP
antagonist-induced cell death [27–30]. To explore a possible role
of caspase-8 activation in LBW242-mediated cell death, we used
cell lines stably transfected with c-FLIPL (A2780WT FLIP,
A2780ADR FLIP and SKOV3 FLIP), a natural caspase-8
inhibitor. A2780WT, A2780ADR and SKOV3 cells express low
levels of c-FLIP, c-FLIPL being the only isoform detectable in
these cells (Fig. 2 and Fig. S2). In contrast, as it is expected,
A2780WT FLIP, A2780ADR FLIP and SKOV3 FLIP express
high levels of c-FLIPL (Fig. 2 and Fig. S2). C-FLIPS was
undetectable in all these cell lines (Fig. S2).
absence ( Control ) or in the presence of LBW242 10 mM, or TRAIL 50 ng/ml or both agents at the above concentrations. In the panel
C both the full length (FL) and the cleaved form (CF) of caspase-3 are shown. The PARP immunoblotting shows two bands, of which the upper
corresponds to a full-length form of PARP and the lower band to a cleaved form of PARP. In the Figure are reported the representative data observed
in one of the three experiments carried out.
doi:10.1371/journal.pone.0035073.g004
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35073Figure 5. LBW242 potentiates the proapoptotic effects of some anticancer drugs, including Cisplatin, Paclitaxel, Topotecan,
Etoposide and Doxorubicin. A- HEY cells have been incubated for 24 h either in the absence (control) or in the presence of LBW242 (30 mM) or of
either Cisplatin (CPLAT at 1.6 or 8 mM) or Paclitaxel (TAXOL at 2.5 or 12.5 mM) or Topotecan (TOPO at 0.2 or 1 mM) or Etoposide (ETOPO at 8 or 40 mM)
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panels) transfected with empty vector (PINCO), the single
treatment with LBW242 or TRAIL induces a moderate apoptotic
effect, while the combined treatment of LBW242 with TRAIL
induces a remarkable increase in cell death. In those cells
overexpressing c-FLIPL (Fig. 2, right panels) the effect of LBW242
treatment alone or in combination with TRAIL is highly inhibited,
thus supporting the hypothesis that SMAC/DIABLO mimetic
may act through induction of a caspase-8 activation pathway.
To this end cells were also treated with a pan-caspase inhibitor
zVAD, or with a specific caspase-8 inhibitor, zIETD; in Fig. 3 the
percentage of cell death was reported. As expected zVAD protects
cells from the apoptotic effect of both single and combination
treatments, thus indicating caspase activation involvement in LBW
242 + TRAIL-mediated cell death. Moreover, it is possible to note
that the effect of zIETD is comparable to that of zVAD, thus
indicating a key role of caspase-8 activation under the combined
action of LBW242 and TRAIL treatments (Fig. 3, left panels).
LBW242 added together with TRAIL induced caspase-8
activation
Biochemical analyses were performed by investigating the
expression of different proteins involved in the apoptotic pathway
in A2780WT PINCO, A2780ADR PINCO, SKOV3 PINCO and
A2780WT FLIP, A2780ADR FLIP and SKOV FLIP cell lines
treated as above mentioned. In Fig. 4 A, B and C after 24 h
treatments, it is possible to note that XIAP levels are not affected
by LBW242. This finding is in line with previous studies showing
that LBW242 inhibits XIAP activity, without affecting its
expression [17–21]. As expected on the basis of previous reports
[17–21], LBW242 dramatically downmodulates c-IAP1 levels,
a phenomenon clearly seen in all cell lines, including those
overexpressing c-FLIPL. Treatment of ovarian cancer cell lines
with LBW242 induced an effect on c-IAP2 expression very
different from that observed for c-IAP1. In fact, 24 h exposure of
the cells to LBW242 induced a clear upmodulation of c-IAP2
levels (Fig. 4), in line with a previous report [31]. As it is expected,
c-FLIPL overexpression did not modify the effect of LBW242 on c-
IAP2 levels (Fig. 4). On the other hand, TRAIL induced
a moderate increase of c-IAP2, a finding in line with previous
studies [32]. Notably, c-FLIP overexpression prevented the
stimulatory effect of TRAIL on c-IAP2 levels (Fig. 4). The
combined treatment with LBW242 and TRAIL resulted in
a marked upmodulation of c-IAP2 levels (Fig. 4). Furthermore,
LBW242 failed to induce either caspase-8, caspase-9 or caspase-3
activation, as it can be inferred from the absence of any significant
reduction of procaspase-8, -9 and -3 levels and of the appearance
of active caspase cleaved fragments (see Fig. 4 A to C and Fig. S3).
In line with these findings, LBW242 failed to induce cleavage of
PARP, a sensitive target of activated caspase-3 (Fig 4A to C).
When LBW242 was added together with TRAIL markedly
potentiated the effect of this death ligand on caspase-8 and
caspase-3 activation and on PARP cleavage in A2780 WT, A2780
ADR and SKOV 3 cell lines transfected with the empty vectors,
but not in those overexpressing c-FLIPL (Fig. 4 A to C). It is
important to note that caspase-8 activation, triggered by TRAIL
and mostly by LBW242+TRAIL, leads to BID degradation, thus
achieving the activation of the intrinsic apoptotic pathway (Fig. 4
A to C). Bid degradation was almost completely prevented by c-
FLIP overexpression (Fig. 4 A to C).
LBW242 improved the pro-apoptotic effect of anticancer
drugs on ovarian cancer cells
The standard medical treatment of ovarian cancer involves in
first instance the use of platin and taxol anticancer drugs.
Therefore, it seemed of interest to evaluate a possible cooperative
effect of some anticancer drugs, such as cisplatin, taxol, topotecan,
etoposide and doxorubicin in combination with LBW242. Thus,
in a first set of experiments we treated HEY cells with Cisplatin or
Paclitaxel or Topotecan or Etoposide or Doxorubicin, added at
two doses, a lower clinical dose corresponding to the peak dose
observed during infusion of these drugs to cancer patients and
a 5 times higher supraclinical dose, alone or in combination with
a plateau dose of LBW242 (30 mM). The results of this experiment
clearly showed that LBW242 was able to potentiate the cytotoxic
effects of all these drugs (Fig. 5A). Isobologram analysis showed
synergistic anti-tumor activity of LBW242 plus Cisplatin
(CI=0.82) or plus Paclitaxel (CI=0.70) or plus Topotecan
(0.72) or plus Etoposide (CI=0.73) or plus Doxorubicin
(p=0.78). In a second experiment we tested the capacity of
various doses of LBW242 to enhance the cytotoxicity induced by
a clinical dose of Cisplatin, Taxol or Topotecan. This experiment
showed that LBW242 in a dose-dependent manner increased the
cytotoxic response to these drugs, achieving the maximal effects at
20–30 mM dosages (Fig. 5B). Isobologram analysis showed
synergistic anti-tumor activity of LBW242 plus Topotecan
(CI=0.70) or Taxol (CI=0.71) or Cisplatin (CI=0.82).
Based on these findings, in a second set of experiments we
focused our attention on the capacity of LBW242 to enhance the
effects of Topotecan, a drug used in ovarian cancer treatment and
known as a potential caspase-8 activator [33].
In Fig. 6A it is possible to note that Topotecan exerts a marked
pro-apoptotic effect when added in combination with LBW242
and TRAIL in A2780WT PINCO cells; the cell death of tumor
cells caused by these agents when used in combination is greatly
inhibited by the pan-caspase inhibitor zVAD-fmk and therefore is
mainly mediated through caspase activation.
In A2780WT FLIP cells the apoptotic induction triggered by
the association between LBW242, TRAIL and Topotecan is
almost completely inhibited, thus suggesting a major role of
caspase-8 in the induction of tumor cell death (Fig. 6A).
These observations have been confirmed in SKOV3 PINCO
and SKOV3 FLIP cells (Fig. 6A). A role for caspases-8 activation
in Topotecan-induced death of ovarian cancer cells was further
supported by experiments of quantification of caspases-8 activa-
tion. These experiments showed that both in A2780WT and
A2780ADR cells either LBW242 or Topotecan alone induced
caspase-8 activation in a few percentage of cells; however, the two
compounds added together resulted in the caspase-8 activation in
a high percentage of cells (Fig. 6B and C).
or Doxorubicin (DOXO at 0.17 or 0.85 mM) alone or in combination with LBW242 and analysed for induction of cell death by flow cytometry. The data
represent the mean values 6 SEM observed in three separate experiments. Statistical analysis: * p=,0.05; ** p=,0.01; *** p=,0.001. B – HEY cells
have been incubated for 24 h in the presence of increasing concentrations of LBW242either in the absence (Control) or in the presence of Cisplatin
(1.6 mM) or Paclitaxel (2.5 mM) or Topotecan (0.2 mM) and analysed for induction of cell death by flow cytometry. The data represent the mean value
6 SEM observed in three separate experiments. The differences between control and Topotecan (p=,0.001), control and Paclitaxel (p=,0.001) and
control and Cisplatin (p=,0.05) were all significant.
doi:10.1371/journal.pone.0035073.g005
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of primary ovarian cancer cells
Given the results obtained in ovarian cancer cell lines we have
explored whether LBW242 could induce, when added alone or in
combination with TRAIL, apoptosis of primary ovarian cancer
cells. To perform this analysis primary ovarian cancer cells derived
from human tumor biopsies obtained during surgery debulking of
tumor mass of 3 primary and 6 relapsing ovarian cancers have
been isolated and tested for their sensitivity to LBW242. The
clinico-pathological features of these patients are reported in
Table 1. The analysis of the percentage of apoptotic cells and of
the number of living cells was carried out. The nine cases analyzed
displayed a heterogeneous sensitivity to TRAIL, with the majority
of cases (about 60%) displaying a low sensitivity to the apoptotic
effect of this death ligand (Fig. 7). A similar situation was observed
for LBW242, with about 50% of the samples displaying a clear
sensitivity to the SMAC/DIABLO mimetic (Fig. 7). Interestingly,
all these samples displayed also a moderate sensitivity to TRAIL.
The contemporaneous treatment with LBW242 and TRAIL
increased the rate of apoptosis of ovarian cancer cells compared to
the values observed when the cells were grown with TRAIL alone
(p,0.05) or LBW242 alone (p,0.05). Importantly, relapsing
ovarian cancer cells, that are usually chemoresistant displayed
a clear sensitivity to apoptotic triggering by LBW242+TRAIL
addition as well as primary ovarian cancer samples.
When the number of living cells was analyzed we observed that
either LBW242 or TRAIL added alone induced a moderate
decline of the number of living cells, while the decline was clearly
more pronounced when these two agents were added together
(Fig. 7).
Figure 6. A- LBW242 potentiates the proapoptotic effect of Topotecan Hydrochloride, a topoisomerase I inhibitor. A2780WT PINCO and FLIP (top
panels) and SKOV3 PINCO and FLIP (bottom panels) cells have been incubated for 24 h either in the absence (Control) or in the presence of either
DMSO 0.01% or zVAD-fmk 40 mM, Topotecan Hydrochloride 1 mM, TRAIL 50 ng/ml or LBW242+zVAD-fmk, LBW242+Topotecan Hydrochloride,
TRAIL+zVAD-fmk, TRAIL+Topotecan Hydrochloride, Topotecan Hydrochloride +zVAD-fmk, LBW242+TRAIL, LBW242+TRAIL+zVAD-fmk, LBW242+To-
potecan Hydrochloride+zVAD-fmk and analysed for induction of apoptosis by flow cytometry. The data represent the mean values 6SEM observed in
three separate experiments. In A7280 WT PINCO and in SKOV3 PINCO cells LBW242+TOPO induced a proportion of dead cells higher than that
observed with either LBW242 (p=,0.05) or TOPO (p=,0.05). B and C – Evaluation of caspases-8 activation in A2780 and A2780ADR cells incubated
either in the absence (Control) or in the presence of LBW242 or of Topotecan or of both LBW242 and Topotecan. Caspase-8 activity in intact cells was
measured using a caspases-8 specific fluorigenic substrate. Original results from one representative analysis are reported in B, while the mean
values6SEM of the percentages of cells displaying caspase-8 activation are reported in C. The percentage of cells exhibiting activated caspases-8 was
higher both for WT and ADR cells in LBW242 than in NT cells (p=,0.05) and in LBW242+TOPO than in LBW242 or TOPO-treated cells (p=,0.05).
doi:10.1371/journal.pone.0035073.g006
Figure 7. Effect of LBW242, TRAIL or a combination of both agents on cell growth (left upper panel) and induction of apoptosis (right
upper panel) of ovarian cancer cells derived from 3 ovarian cancer at presentation (black bars) and 6 relapsing ovarian cancers
(white bars). The gray bars represent mean values 6 SEM. Ovarian cancer cells isolated from tumor biopsies have been grown for 24 hours either in
the absence or in the presence of LBW242 (10 mM) or of TRAIL (50 ng/ml) or both agents at the above concentrations. Lower panel on the right: The
proportion of dead cells was higher in LBW242 or TRAIL or LBW242+TRAIL-treated cells than in control not-treated cells (p=,0.01); furthermore, the
percentage of dead cells was lower in LBW242+TRAIL than in TRAIL or LBW242-treated cells (for both p=,0.05). Lower panel on the left: The cell
number was significantly lower in LBW242+TRAIL than in TRAIL or LBW242-treated cells (for both p=,0.05).
doi:10.1371/journal.pone.0035073.g007
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Previous studies based on the enforced expression of SMAC/
DIABLO into ovarian cancer cell lines have provided initial
evidences indicating that through this way apoptosis can be
induced in ovarian carcinoma without damaging normal ovarian
tissue [34,35]. Alternatively, apoptosis of ovarian cancer cells can
be induced using small peptides, such as compound 3, that act as
SMAC/DIABLO mimetics [24]. Recently, more potent IAP
inhibitors were synthesized and some of them, like LBW242,
entered phase I clinical studies [17–21].
It is of fundamental importance in the studies on these
compounds, as well as on other new anticancer drugs, to identify
candidate cancer types suitable for subsequent clinical studies.
Given our previous studies with the compound 3 SMAC/
DIABLO mimetic on ovarian cancer, it seemed particularly
interesting to extend these studies to LBW242. The main
objectives of the present study consisted in determining: (a) the
sensitivity of ovarian cancer cell lines and particularly of those
chemoresistant, as well as of primary ovarian cancer cells, to
LBW242-mediated apoptosis; (b) whether the treatment with
LBW242 sensitizes ovarian cancer cells to TRAIL-mediated
apoptosis; (c) whether LBW242 potentiates the cytotoxic effects
of some anticancer drugs used in the treatment of ovarian cancer.
Concerning the first point, we observed that treatment of
ovarian cancer cells with LBW242 resulted in a moderate
inhibitory effect on cell proliferation, in part due to induction of
apoptosis of these cells. These observations were in line with
previous studies carried out on other cancer cell types [17–21]. It is
important to note that LBW242 was equally active in inhibiting
the growth of both chemosensitive and chemoresistant ovarian
cancer cell lines, as well as of fresh ovarian cancer cells derived
from primary and relapsing tumors.
Concerning the second point, we observed that LBW242, like
SMAC/DIABLO mimetic compound 3 [24], sensitized ovarian
cancer cells to the pro-apoptotic effects of TRAIL. These
observations are potentially interesting because they provided
evidence that the combined addition of LBW242 and TRAIL
resulted in the massive cell death of all ovarian cancer cell types
here analyzed, including those derived from relapsing ovarian
cancer patients. The potentiation of TRAIL-mediated apoptosis
by LBW242 seems to be related to the capacity of IAP inhibitors to
favor caspase-8 activation, as previously indicated in various
reports [27–30]. In particular, using other SMAC/DIABLO
mimetics, it was shown that c-IAP1 degradation induced by the
mimetics leads to formation of caspase-8 activation complex
involving procaspase-8, FADD and RIP1, RIP1 being required for
pro-apoptotic activity [36–37]. In our experiments, this conclusion
is supported by various lines of evidence: (i) overexpression of c-
FLIPL, a natural caspase-8 inhibitor, in ovarian cancer cell lines
resulted in a protection against the pro-apoptotic effects elicited by
LBW242 alone or in combination with TRAIL; (ii) addition of
a synthetic cell-permeable caspase-8 inhibitor, zIETD-fmk, to
ovarian cancer cells resulted in a marked inhibition of
LBW242+TRAIL-induced apoptosis. These findings substantiate
the essential role of caspase-8 in tumor cell apoptosis elicited by
IAP inhibitors. It is important to note that a previous study showed
that down-regulation of c-FLIP in tumor cells including ovarian
cancer, enhances apoptosis induced by SMAC/DIABLO mimetic
compounds [38]. In this context, it is of interest to note that recent
studies suggest an important role for a caspase-8 gene poly-
morphism in the susceptibility to develop ovarian cancer and
breast cancer [39,40].
Previous studies have shown that some cancer cell lines evade
Smac mimetic-induced apoptosis by upregulating c-IAP2, which
although initially degraded, rebounds and it is refractory to
subsequent degradation [31,41]. We confirmed this phenomenon
of c-IAP2 upmodulation by LBW242. C-IAP2 upmodulation
induced by LBW242 in ovarian cancer cells could induce some
resistance to apoptosis; however, this inhibition was overcome by
the addition of TRAIL to the SMAC/DIABLO inhibitor.
Concerning the third point, we have explored a possible
potentiating effect of LBW242 on tumor cell death induced by
some anticancer drugs. Particularly, we described that LBW242
synergizes with Cisplatin, Taxol, Topotecan, Etoposide and
Doxorubicin in inducing ovarian cancer cell death. It is important
to point out that this stimulatory effect of LBW242 on the
cytotoxic effects mediated by anticancer drugs is exerted both on
drugs used in first line (cisplatin and taxol) and in second line
(topotecan, etoposide and doxorubicin) treatments. These ob-
servations are in line with previous studies providing evidence
about a potentiation of antileukemic on anti-multiple myeloma
Table 1. Clinical characteristics of the nine ovarian cancer patients whose tumor samples were Investigated for sensitivity to
LBW242.
PATIENT AGE
Clinical
Stage
FIGO
Stage Pathology Tumor Site Therapy
1 62 Primary III c Scarcely differentiated serous carcinoma Peritoneum 3c Carboplatin-Taxol
2 81 Primary I a Scarcely differentiated
endometrioid carcinoma
Ovary 6c Carboplatin-Taxol
3 39 Primary III c Serous carcinoma Ovary 3c Carboplatin-Taxol
4 81 Relapse III c Serous carcinoma Peritoneum 6c Carboplatin-Taxol
5 71 Relapse III c Serous carcinoma Omentum +
Peritoneum
6c Carboplatin- Taxol
6 59 Relapse IV ADC-Serous carcinoma Omentum 5c Cisplatin-
Farmoribicin-Taxol
7 60 Primary III c Serous carcinoma Ovary 3c Carboplatin-Taxol
8 41 Relapse III c Serous carcinoma Peritoneum 8c Paclitaxel-
carboplatin
9 55 Relapse III c Papillary-cystic carcinoma Omentum 8c Carbo-taxol
doi:10.1371/journal.pone.0035073.t001
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interesting was a recent report showing that LBW242 enhanced
esophageal squamous cell carcinoma cisplatin-induced apoptosis
and caspase activation and restored cisplatin sensitivity in SMAC-
deficient tumor cells [42].
We observed that LBW242 clearly potentiated the in vitro
antitumor effects of Topotecan, a topoisomerase I inhibitor,
known as a potential caspase-8 activator [31]. The cell death
induced by LBW242+Topotecan Hydrochloride was at large
extent inhibited by either c-FLIPL overexpression or zIETD-fmk,
thus suggesting that the two drugs cooperate in inducing caspase-8
activation. Interestingly, we observed also that LBW242 potenti-
ated the cytotoxic effect of Etoposide. This finding may be related
to the different capacity of these two compounds to mediate the
degradation of IAP machinery, Etoposide being capable of
inducing c-IAP1, c-IAP2, XIAP and, most importantly c-FLIPL
degradation, as shown by a recent study [43].
In conclusion, the results of the present study indicate that the
IAP inhibitor LBW242 is active in mediating inhibition of ovarian
cancer cells, particularly when acting in combination with TRAIL
or with some antineoplastic drugs. These observations may
represent the preclinical rationale for future experimental studies
of small molecule inhibitors in combination with TRAIL or with
some antineoplastic drugs.
Supporting Information
Figure S1 Effect of LBW242 on the cell growth of
A2780WT, A2780ADR, HEY and SKOV3 cells. The data
are identical to those reported in Fig. 1A, but are plotted using
measurements at LBW242 0 mM with and without TRAIL as
100% and all the subsequent measurements expressed relative to
its own control.
(TIF)
Figure S2 Immunoblotting analysis of c-FLIP in
A2780WT PINCO and FLIP (A), A2780ADR PINCO and
FLIP (B), SKOV3 PINCO and SKOV3 FLIP (C) cells
grown for 24 h either in the absence ( Control ) or in the
presence of LBW242 10 mM, or TRAIL 50 ng/ml or both
agents at the above concentrations.
(TIF)
Figure S3 Immunoblotting analysis of Casp-3, Casp-8
and Casp-9 in A2780WT PINCO and FLIP (A), A2780ADR
PINCO and FLIP (B), SKOV3 PINCO and SKOV3 FLIP
(C) cells grown for 24 h either in the absence ( Control )
or in the presence of LBW242 10 mM, or TRAIL 50 ng/ml
or both agents at the above concentrations. The cleavage
bands of 43/41 kDa for caspase-8, of 37/35 kDa for caspase-9
and of 17 kDa for caspase-3 are shown.
(TIF)
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